An organized approach to the Danusertib research buy haemodynamic support to sepsis includes use of fluid resuscitation, vasopressor therapy and inotropic therapy. A multidisciplinary approach to the management of critically ill patients may be an important factor in the quality of care. Appendices Appendix 1. Antimicrobial therapy for community-acquired extrabiliary IAI in no critically ill patient, in absence of risk factors for ESBL Community-acquired
extrabiliary IAI No critically ill patient No risk factors for ESBL AMOXICILLIN/CLAVULANATE Daily schedula: 2.2 g every 6 hours (Infusion time 2 hours) OR (Allergy to beta-lactams): CIPROFLOXACIN Daily schedula: 400 mg every 8 hours (Infusion time 30 min) + METRONIDAZOLE Daily schedula: 500 mg every 6 hours (Infusion time 1 hour) Appendix 2. Antimicrobial therapy for Epacadostat research buy community-acquired extrabiliary IAI in no critically ill patient, in presence
of risk factors for ESBL Community-acquired extrabiliary IAI No critically ill patient Risk factors for ESBL ERTAPENEM Daily schedula: 1 g every 24 hours (Infusion time 2 hours) OR TIGECYCLINE Daily schedula: 100 mg LD then 50 mg every 24 hours (Infusion time 2 hours) Appendix 3. Antimicrobial therapy for community-acquired ACP-196 ic50 extrabiliary IAI in critically ill patient, in absence of risk factors for ESBL Community-acquired extrabiliary IAI Critically ill patient (± also SEVERE SEPSIS) No risk factors for ESBL PIPERACILLIN/TAZOBACTAM Daily schedula: 8/2 g LD then 16/2 g/die by continuous infusion or 4.5 g every 6 hours
(infusion time 4 hours) Appendix 4. Antimicrobial therapy for community-acquired extrabiliary IAI in critically ill patient, in presence of risk factors for ESBL Community-acquired IAI Critically ill patient (± SEVERE SEPSIS) Risk factors for ESBL MEROPENEM Daily schedula: 500 mg every 6 hours (Infusion time 6 hours) OR IMIPENEM Daily schedula: 500 mg every 4 hours (Infusion time 3 hours) +/- FLUCONAZOLE Daily schedula: 600 mg LD then 400 mg every 24 hours (Infusion time 2 hours) Appendix 5. Antimicrobial therapy for biliary IAI in no critically ill patient, in absence of risk factors for ESBL Community-acquired biliary IAI No critically ill patient No risk factors for ESBL AMOXICILLIN/CLAVULANATE Daily schedula: 2.2 g every 6 hours (Infusion time 2 hours) OR (Allergy to beta-lactams) CIPROFLOXACIN Daily schedula: 400 mg every 8 hours (Infusion time 30 min) + METRONIDAZOLE Daily schedula: 500 mg every 6 hours (Infusion time 1 hour) Appendix 6. Antimicrobial therapy for biliary IAI in no critically ill patient, in presence of risk factors for ESBL Community-acquired biliary IAI No critically ill patient Risk factors for ESBL TIGECYCLINE Daily schedula: 100 mg LD then 50 mg every 12 hours (Infusion time 2 hours) Appendix 7.